This was a week of narrowing. Steris and Labcorp each paid up for revenue they can already see, Siemens Healthineers walked out of a product category it helped build a reputation in, and J&J conceded that its medtech engine has downshifted two quarters running. The most quietly encouraging number of the week came from an insulin pump trial where only one in nine participants had ever counted a carbohydrate, and it worked anyway.
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
8 things to watch this week:
1. 🏭 Steris pays $2.1B for positioning pads and turnover kits
Steris will buy Xodus Medical for $2.1 billion, with up to $150 million more in earnout through 2028. About $300 million in tax benefits takes the net to roughly $1.8 billion against an estimated $245 million of 2026 revenue. Xodus makes patient positioning pads, bed straps, OR turnover kits and laparoscopic defogging hardware. Steris is paying a growth multiple for consumables, not technology. It is the clearest signal yet that recurring hospital spend is the asset class everyone wants.
MassDevice
2.📉 J&J’s medtech engine downshifts again
MedTech sales hit $8.64 billion in Q3, up 2.5% year over year, after growing above 7% in both Q1 2026 and Q4 2025. Surgery fell 0.6%. Abiomed slid 2.3% to $412 million, its second straight decline, which Tim Schmid pinned on lower Impella volume after an unfavorable UK study and called a temporary headwind. Two quarters is a pattern, not a blip, and the PROTECT IV readout that would settle the argument does not arrive until next year.
MedTech Dive
3. 🤖 The AMA draws a line around clinical AI agents
The AMA published a governance framework for agentic AI taking on clinical functions, built on four questions: what function the AI performs, what evidence shows it can, what it should be permitted to do and under what conditions, and who owns the risk when it fails. The stated principle is that clinical authority is earned through evidence and kept through demonstrated performance. Device makers shipping autonomous features should read this as the liability conversation starting without them.
American Medical Association
🧰 Your best engineer shouldn’t be building the investor deck.
Device teams are staffed for engineering, regulatory, and quality. The commercial case is a different job: positioning, the investor and sales materials, the website, the story a buyer actually hears. It lands on whoever has room that week, or gets split across vendors who never speak to each other. RŌG Health builds the whole set as one group, with specialists on the parts that need them. We were Scientia Vascular’s strategic and creative partner for five years, right up to the end; Scientia was acquired by Medtronic this year for $550 million. Start with a conversation about where your case is thin.
Sponsored by RŌG Health
4. 🧪 Labcorp buys the rest of BioReference
Labcorp will pay Opko Health $722 million upfront plus up to $150 million tied to 4Kscore revenue for BioReference’s clinical and women’s health testing, its correctional-facility urology services and more than 80 patient service centers. Labcorp expects roughly $250 million of revenue in the first year after closing. This finishes the job it started in March 2025 with BioReference’s oncology assets, and it buys national distribution for a prostate test that never escaped New York and New Jersey.
MedTech Dive
5. 🩻 Siemens walks out of general ultrasound
As of October 12, Siemens Healthineers no longer sells its Acuson Sequoia, Redwood, Juniper or Maple general imaging ultrasound systems. It will keep servicing the installed base and will sell only procedural platforms: Acuson Origin, the P500 intracardiac echo system and Freestyle, aimed at electrophysiologists and interventional cardiologists. Trading a commoditized imaging category for catheter-adjacent margin is a coherent bet. It also hands general ultrasound to its remaining rivals and the handheld entrants without a fight.
AuntMinnie
6. 💉 twiist clears for type 2, and the trial population is the story
FDA cleared Sequel Med Tech’s twiist automated insulin delivery system for adults with insulin-treated type 2 diabetes, roughly 5.5 million more Americans. In the 307-patient twiist-T2D trial, A1c fell 0.7% from a baseline of 8.1%, time in range rose 16 points to 73%, and no severe hypoglycemia was reported. Only 11% of participants had ever counted carbohydrates. Pumps have spent two decades selling to the motivated minority. This is the first credible claim on everyone else.
Sequel Med Tech
7. ⚠️ Edwards pulls delivery lots ten months into a launch
FDA issued an early alert on October 15 covering four lots of Edwards Lifesciences’ Commander M delivery system, used to place the Sapien M3 mitral valve, after three reports of balloons bursting during inflation. One death and one serious injury were reported as of October 5, across fewer than 200 affected systems. Sapien M3 was approved in December 2025 for patients unsuitable for surgery, which is precisely the population least able to absorb a bailout procedure.
TCTMD
8. 🌐 China opens comment on export curbs covering AI models
Beijing’s commerce and science ministries proposed adding 40 technologies to China’s export control catalog, with comment open until November 15. Twenty-three are AI items, including large models, intelligent agents and compute clusters. Five are biomedicine, covering cell and gene therapy and nucleic acid drugs. No device categories are named. The exposure is indirect but real: any device software built on a Chinese open-weight model now carries a policy risk line in its regulatory file.
Xinhua
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.